Immuno-Oncology | Specialty

Dr. Seiwert on Final Thoughts on Immunotherapy in Head and Neck Cancer

May 1st 2017

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some final opinions on immunotherapy agents in the landscape of head and neck cancer.

FDA Approves Durvalumab for Bladder Cancer

May 1st 2017

The FDA has granted an accelerated approval to the PD-L1 inhibitor durvalumab (Imfinzi) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Novel Agents for Multiple Myeloma

April 28th 2017

Emerging Combination Therapies for Myeloma

April 28th 2017

Therapy Choice at Myeloma Progression

April 28th 2017

Treatment for Relapsed/Refractory Multiple Myeloma

April 28th 2017

Patient Selection for Ixazomib in Myeloma

April 28th 2017

Proteasome Inhibitor Use in Myeloma

April 28th 2017

EU Approval of Ixazomib for Relapsed/Refractory Myeloma

April 28th 2017

Defining Progression in Multiple Myeloma

April 28th 2017

Early versus Late Response in Multiple Myeloma

April 28th 2017

Maintenance Therapy in Multiple Myeloma

April 28th 2017

Transplant Timing in Multiple Myeloma

April 28th 2017

Upfront Therapy for Myeloma; Impact on Choice at Relapse

April 28th 2017

The Ever-Changing Landscape of Myeloma Therapy

April 28th 2017

Dr. Drake Discusses Immunotherapy Agents in Bladder Cancer

April 28th 2017

Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses immunotherapy agents in bladder cancer.

Intriguing Immunotherapy Regimens Investigated in MCL

April 28th 2017

Grzegorz S. Nowakowski, MD, discusses the ever-changing landscape of mantle cell lymphoma, the intriguing combinations being studied, and the promise that immunotherapy could hold.

Dr. Papa on the Impact of CAR T Cell Trial in Head and Neck Cancer

April 27th 2017

Sophie Papa, PhD, MBBS, MRCP, medical oncologist, Clinical Academic Group, Department of Research Oncology, King’s College London, discusses the impact of a recent study of chimeric antigen receptor (CAR) T cells in head and neck squamous cell carcinoma.

Immunotherapy Demonstrates Early Promise Across Lymphoma Subgroups

April 27th 2017

Stephen M. Ansell, MD, PhD, discusses the potential of immunotherapy agents in lymphoma, ongoing clinical trials, and where this blends in with chimeric antigen receptor (CAR) T-cell therapy.

Future Research Efforts for ALK-Driven Lung Cancer

April 27th 2017